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Aims The aim of this study was to assess the reproducibility of flow-mediated dilatation (FMD) in a multicentre setting.
Methods
and results
This studywas performed as part of the dal-VESSEL trial inwhich FMDwasmeasured in 19 vascular imaging centres in six
European countries. A subgroupof patientswhowere allocated in the placebo group and scanned twice at each trial time
point (substudy) was analysed. Intra-sonographer variability was calculated fromFMDmeasurements 48 h apart. Centre
variability and short-,medium-, and long-termreproducibilityof FMDwerecalculated at 48 h andat3 and 9months inter-
vals, respectively. Intra- and inter-reader variability was assessed by re-analysing the FMD images by three certified
readers at two time intervals, 7 days apart. Sixty-seven patients were included. Variability between centres was compar-
able at 48 h and 3months interval but almost doubled at 9months. Themean absolute difference in %FMDwas1.04, 0.99,
and 1.45%at the three time intervals, respectively.Curveswere generated to indicate the numberof patients required for
adequate power in crossover and parallel study designs.
Conclusion This study demonstrates for the first time that in amulticentre setting reproducible FMDmeasurements can be achieved
for short- andmedium-term evaluation, which are comparablewith those reported from specialized laboratories. These
findings justify the use of FMD as an outcome measure for short- and medium-term assessment of pharmacological
interventions.
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Introduction
Atherosclerosis begins in early life. Strategies to study and manage
‘lifetime’ risk from atherosclerosis require robust intermediate phe-
notypes, on the causal pathway for disease.1,2 Endothelial function is
linked to cardiovascular (CV) risk factors,3,4 provides prognostic in-
formation,4–6 and can be studied non-invasively by measurement of
flow-mediated dilation (FMD).7 Flow-mediated dilation reflects local
nitric oxide bioavailability and enables both examination of mechan-
isms involved in the initiation and progression of pre-clinical vascular
disease and the impact of acute and long-term interventions.7
The ‘dynamic’ nature of the technique is also responsible for some
of its limitations. Flow-mediated dilatation is known to be affected by
a wide range of biological, environmental, and methodological
factors.8 To ensure accurate assessment of endothelial function,
such parameters need to be considered and controlled for carefully
in studies utilizing FMDas an outcomemeasure. Reliable evidence on
the reproducibility and variability of FMD is essential for experimen-
tal protocol design.Our group have reported such data in the setting
of a single experienced FMD laboratory.8 We subsequently demon-
strated similar findings in a very large, single-centre epidemiological
study in children.9
Evaluation, however, of the long-termeffects of an intervention on
endothelial function necessitates a multicentre approach. This intro-
duces additional sources of variability in FMD, which have not yet
been quantified. dal-VESSEL is the first multicentre trial with FMD
as its primary endpoint to assess the safety and effect on endothelial
functionof the cholesteryl ester transfer protein inhibitordalcetrapib
in patientswith coronary heart disease.10 This studyprovided theop-
portunity to assess the short-, medium-, and long-term variability of
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FMD in amulticentre setting but also enabled construction of power
curves to assist in the design of clinical trials where endothelial func-
tion is used as outcome measure to evaluate the effects of various
therapeutic interventions.
Methods
Study design
This studywasperformed as part of the dal-VESSEL trial (clinicaltrials.gov
number NCT00655538).11 In brief, in a randomized double-blinded par-
allel trial, the effects of dalcetrapib and placebo treatment on brachial
artery flow-mediated dilatation were compared after 3 and 9 months
duration in 476 patients. The study protocol was approved by the institu-
tional review boards or ethical committees from participating institu-
tions. Informed consent was obtained from all patients before entering
the study. Principle findings have already been reported.11
Prior to recruitment, a formal training programme was developed in-
corporating a common equipment platform and scanning protocol and
two centralized training sessions run by experienced teachers. All sono-
graphers were certified by a pre-specified programme developed at a
central core FMD laboratory (LondonCore Lab, London,UK). Thirty-six
sonographers were certified and performed the endothelial function
measurements in 19 vascular imaging centres in six European countries.
To assess FMD variability and reproducibility, a subset of up to 35% of
dal-VESSEL trial participants were scanned twice, at each trial time-point
(baseline, 3months, 9months; see ‘Study Protocols’ for details). All scans
included in the variability and reproducibility ‘substudy’ of the dal-VESSEL
trial incorporated patients whowere assigned to the placebo group. The
scans were analysed by three expert readers (London Core Lab: M.C.,
S.P.L.; A.M.C. Vascular Imaging Amsterdam: J.W.) to assess inter- and
intra-reader variability (see ‘Study Protocols’ for further details).
Brachial B-mode ultrasound imaging
Prior to FMD assessment, patients were asked to adhere to the prepar-
ation requirements for the scan. All the patients were requested to fast,
starting at least 12 h prior to the scan, as well as refrain from strenuous
exercise during that period. Caffeine, smoking, and intake of vitamin C
were not allowed from 6 h prior to the scan.12 Regular medication was
continued, but no other medication was allowed prior to the FMD scan.
Female participants were postmenopausal. Measurements took place in
quiet, temperature-controlled (20–248C) rooms. Subjects remained at
rest in the supine position for 15 min prior to the start of the scan.
B-mode ultrasound scans of the right brachial artery were obtained
using a Sonix SP ultrasound machine (Ultrasonix, Vancouver, Canada)
equipped with a 7.5 MHz linear array transducer. An especially designed
arm-rest and probe holder was constructed to optimize standardization
of the position of the ultrasound probe. A blood pressure cuff was placed
in the forearm 1 cm below the antecubital fossa. Measurements were
obtained during 1 min, afterwhich the blood pressure cuff was inflated to
250 mmHg in order to interrupt blood supply. Following 5 min of
forearm ischaemia, the cuff was released and brachial diameter measure-
mentswerecontinuously recorded for3 min aftercuff releaseBloodflow
velocity and heart rate were continuously monitored by pulsed-wave
Doppler and displayed as a spectral Doppler curve. Image acquisition
was ECG gated on the R-wave and the ultrasound images saved in a
Digital Imaging and Communications in Medicine clip. To ensure the
secure and regulatory compliant transmission of data from the image ac-
quisition sites to the centralized server, a standard device data transfer
box was utilized (CERTU Medical, Amsterdam, The Netherlands).
Image analysis
Offline analysis of acquired images was performed in a ‘blinded’ fashion
using customized software (Brachial Analyser, Medical Imaging Applica-
tions, Iowa, USA). For image analysis, the reader selected a region of
interest in the longitudinal image of the brachial artery. Upon definition
of the correct interfaces of the scan, the Brachial Analyser software per-
formed an automated tracing of the lumen–wall boundaries of the near
and farwall of the images of the clip of the scan.13 The software quantified
a brachial artery lumen diameter for each image of the scan, before and
after cuff occlusion. Average baseline diameter and the maximum
post-cuff deflation diameter were used to calculate the absolute (peak
diameter 2 baseline diameter) and percentage FMD [(peak diameter2
baseline diameter)/baseline diameter] * 100.
The velocity-time integral (VTI) was measured from spectral Doppler
curves, using automated flowanalysis software (Medical ImagingApplica-
tions, Iowa, USA). The VTI was calculated for each R-wave-triggered
cardiac cycle as a per cent increase from baseline. Measurements were
made three times at baseline and during reactive hyperaemia (peak VTI
following cuff release). Blood flow and reactive hyperaemic response
were also calculated (Supplementary material online, formulae). Flow-
mediated dilatation corrected for shear stress was obtained by dividing
%FMD by the hyperaemic velocity-time integral.
Sources of variability
Sonographer performance and intra-sonographer
reproducibility
Sonographers were eligible to scan patients in the study following suc-
cessful certification. This involved attendance in at least two training ses-
sions organized by the Core Lab, and completion of certification process
which involved 10 repeat scans with ,2% variability in %FMD. The
number of accepted and rejected scans per sonographer was closely
monitored and re-certification was performed when rejection of .2
consecutive scans were identified from the same sonographer. To
assess intra-sonographer repeatability, a subset of 35% of trial partici-
pants were scanned twice by the sonographers 48 h apart.
Centre performance and variability
Centre performance was established by assessing the recruitment
process and the number of accepted and rejected scans in the efficacy
phase. Centre variability was established by analysing repeat measure-
ments of FMD at each of the dal-VESSEL trial outcome points from the
patients who agreed to participate in the substudy. This variability incor-
porates inter-sonographer variability, as repeat measurements were not
alwaysperformedby the samesonographer.Variabilitywascalculated for
centreswhere.3 patients were recruited from the placebo group. Ana-
lysis of the FMD images were performed by two readers (S.L. and M.C.)
and calculation of short-, medium-, and long-term variability per centre
was performed.
Short-term variability of flow-mediated dilatation
To assess ‘short-term’ variability, FMD measurements were performed
twice in ‘substudy’ participants within 48 h. This took place at the start
of the dal-VESSEL trial, during baseline assessment of FMD and other
relevant clinical parameters (visit 1; V1). We compared brachial artery
baseline diameter, FMD (absolute and percentage), and flow stimulus
measurements between the two scans. Subjects without a valid pair of
scans at V1 were excluded from the present and all other protocols.
Medium- and long-term variability of flow-mediated
dilatation
Study participants completing short-term variability, underwent repeat
measurements of FMD (within 48 h) at each of the dal-VESSEL trial
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outcome time-points (3 and 9 months). Images from repeat FMD scans
were used to assess ‘medium-’ (within 3 months) and ‘long-term’
(within 9months) FMDvariability.We compared brachial artery baseline
diameter, FMD (absolute and percentage), and flow stimulus measure-
ments between: (i) scans from patients in the dal-VESSEL trial placebo
group at baseline (V1) and at 3 months (visit 2; V2) (‘medium-term’
variability); (ii) scans from patients in the dal-VESSEL trial placebo
group at V1 and at 9 months (visit 3; V3) (‘long-term’ variability).
Intra- and inter-reader variability of flow-mediated
dilatation
To assess ‘reader’ reproducibility, 95 images were re-anonymized, and
analyses were performed at least 7 days apart. We compared brachial
artery baseline diameter and FMD (absolute and percentage) measure-
ments between analyses of individual scans: (i) evaluated by a single
reader (‘intra-reader’ variability); (ii) evaluatedbyall three readers (‘inter-
reader’ variability).
Statistical analysis
All measures are expressed as mean+ standard deviation or median
(range) unless otherwise stated. Flow-mediated dilatation (and other
measured parameter) variability (‘short-’, ‘medium-’, and ‘long’-term
and centre variability) was expressed as the absolute difference in pairs
ofmeasurements between time-points. Reproducibility of differentmea-
surements was assessed by using intraclass correlation coefficient (ICC),
technical errorof measurement (TEM), and coefficient of variation (CV).
Coefficient of variation within such pairs was defined as standard devi-
ation of the difference between paired values divided by the mean and
dividedby the
NameMeNameMe
2
√
.8 The formulae used are available in the Supplementary
material online. Mountain plot and Bland–Altman plots for the various
measurements were generated to further assess FMD variability
between the various study time-points. Similar statistical methods were
used to assess ‘intra-’ and ‘inter-’ reader reproducibility.
To assess the number of subjects required for a parallel and crossover
multicentre study for 80% statistical power and 5% significance, and to
assess the effect of varyingCVbetween centres, power curveswere con-
structed from between and within subject variances as previously
reported.8 All statistical analyses were performed using the STATA
12.1 software (STATAcorp, TX, USA).
Results
Study participants
Four hundred and seventy-six patients were randomized to partici-
pate in the study in 19 clinical centres. From those 375 had valid
FMD assessment at baseline and 3 months (visit 2) and 310 had
valid FMD measurements at 9 months (visit 3).
Sixty-seven patients who participated in the substudy assessment
and were in the placebo group were included to assess methodo-
logical variability (14% of the total number of patients randomized
in the dal-VESSEL trial).10 Data collected from these patients were
used to assess centre, intra-sonographer variability, and the ‘short’,
‘medium’, and ‘long-term’ variability of FMD. Demographic and clin-
ical characteristics of all participants in our study are summarized in
Table 1. Therewas nodifference in the demographic and clinical char-
acteristics of the participants over the 9-month follow-up period.No
changes in patient’s regular medication were made over the study
period.10
Sources of variability
Sonographer performance and intra-sonographer
variability
Thirty-six sonographerswere certified and eligible to scan patients in
the study. The median accepted number of scans per sonographer
over the 9-month period of the study was 24 (1, 175) scans,
whereas the median rejected number was 12 (0, 54) scans.
The intra sonographer variability was calculated in 10 sonogra-
phers from patients in the placebo group. The range for absolute
TEM was 0.5–1.1%.
Centre performance and variability
A total number of 2195 scans were performed in 19 centres. The
number of scans performed in different centres varied from 17 to
291 for the one with the highest recruitment rate. The total
number of rejected scans was 662 (30% of total number of scans).
Reasons for rejection were mostly technical (i.e. inadequate image
quality due to patient movement, inadequate ECG triggering),
which precluded reliable image analysis. The mean rejection rate
was 8.7% at baseline and remained at the same level 9% at 3-month
evaluation (visit 2),whereas increased to 15%at 9-month assessment
(visit 3).
There were 12 centres where serial FMD measurements were
performed in the placebo group. From those, only six centres had
recruited ≥3patients from the placebo group and consistently fol-
lowed them up in the serial assessment. For all centres the short-
and medium-term variability was better than the long-term one.
The short- and medium-term reproducibility were comparable
between centres (absolute TEM ranged from 0.4 to 1.4%) while
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of participants in the
variability study of the dal-VESSEL trial
Study participant characteristics
Male (%) 83 (88.3)
Placebo (%) 47 (50.0)
Age (years) 61.3+8.1
Body mass index (kg/m2) 28.4+4.6
Coronary heart disease (%) 65 (69.4)
Smoking (%) 25 (26.6)
Type II diabetes mellitus (%) 35 (37.5)
Fasting glucose (mg/dL) 6.4+1.6
HbA1c (%) 6.3+0.9
Total cholesterol (mg/dL) 145.6+22.4
HDL cholesterol (mg/dL) 38.1+7.6
LDL cholesterol (mg/dL) 80.2+7.6
Brachial artery baseline diameter (mm) 4.6+0.7
Reactive hyperaemia (%) 450+191.7
Absolute FMD (mm) 0.2+0.1
FMD (%) 4.1+0.9
Reactive blood flow (mL/min) 20.5+7.3
Delta blood flow (mL/min) 16.4+6.3
Variables expressed as number (percentage) or mean+ standard deviation.
FMD, flow-mediated dilatation.
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increased up to 2.5% at 9-month interval. There was no difference in
the reproducibility for %FMDbetweencentreswithhigherand lower
recruiting rate.
Short-term variability of flow-mediated dilatation
The mean absolute difference in %FMD between values obtained at
V1, 48 h apart, was 1.04% and there was good correlation between
values (ICC: 0.8) (Table 2). A Bland–Altman plot of the ‘short-
term’ %FMD variability data is shown in Figure 1A. Similar variability
results were obtained for absolute FMD (FMDAbs). The reproduci-
bility for brachial artery diameter (BLD) was superior to %FMD
(Table 2), whereas poor intraclass correlation was seen for reactive
hyperaemia (Table 2 and Bland–Altman plots in the Supplementary
material online). The FMD/VTI had lower reproducibility compared
with %FMDandFMDAbs.Noassociationwasnotedbetween %FMD
and reactive hyperaemia.
Medium- and long-term variability of flow-mediated
dilatation
The median absolute difference in %FMD between V1–V2
(3 months) and V1–V3 (9 months) was 0.99 and 1.45%, respectively
(Table 2). There was good correlation between %FMD values at V1
and V2 (ICC: 0.74), which was comparable with that observed for
short-term variability. Correlation was poorer between %FMD
values at V1 and V3 (ICC: 0.58). Technical error of measurement
and CV results for %FMD over 3 and 9 months are summarized in
Table2. Bland–Altmanplotsof ‘medium-’and ‘long-term’ FMD%vari-
ability data are shown in Figure 1B and C, respectively. Similar variabil-
ity results were obtained for FMDAbs. Baseline diameter
reproducibility was excellent during the course of the study
(Table 2 and Bland–Altman plots in the Supplementary material
online). High variability for the reactive hyperaemic response was
seen in medium- and long-term assessment (Bland–Altman plots
in the Supplementary material online). The reproducibility for
FMD/VTI was also poor.
Weconstructedpowercurves fromthedata recordedat3months
and 9 months apart for crossover and parallel studies. The graphs
clearly demonstrate that adoption of a complex crossover design
will significantly reduce the number of patients required for the clin-
ical trial (Figure 2).
Intra- and inter-reader variability of flow-mediated
dilatation
‘Intra-’ and ‘inter-reader’ reproducibility for FMD% was excellent.
There was no systematic bias between the first and second read of
the same reader. The ICC rangewas 0.84–0.99 for the intra-rater re-
producibility and 0.82–0.87 for the inter-rater reliability.
Discussion
This studydemonstrates, for thefirst time, thatwithoptimal sonogra-
pher training and adherence to strict and standardized protocols,
endothelial function can be assessed serially using flow-mediated
dilatation in a multicentre setting in patients with coronary artery
disease. The short- and medium-term reproducibility of %FMD ap-
proximate those reported from single centres. The power curves
which have been constructed incorporating the biological and tech-
nical variability of the method suggest that a relative small number of
patients are required to detect differences in %FMDboth for a cross-
over and parallel study design trial. These results validate the use of
thismethodas an intermediateendpoint for short- andmedium-term
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Table 2 Reproducibility of flow-mediated dilatation in a multicentre setting
FMD abs (mm) FMD (%) %FMD/VTI peak (%/cm) BLD (mm) React hyper (%)
V1 0.18 (0.08) 4.1 (1.9) 6.7 (4.0) 4.6 (0.7) 555.8 (197.4)
V1 + 48 h 0.18 (0.08) 4.1(2.2) 6.7 (5.9) 4.5 (0.7) 586.5 (216.0)
V2 0.19 (0.09) 4.2 (2.2) 6.7 (4.0) 4.6 (0.7) 596.6 (205.5)
V3 0.19 (0.10) 4.1 (2.5) 5.1 (3.4) 4.7 (0.7) 572.8 (217.4)
Absolute TEM
V1–V148 h 0.042 0.92 3.3 0.15 5.6
V2–V1 0.047 1.1 2.5 0.09 5.2
V3–V1 0.067 1.5 2.5 0.06 5.3
Coefficient of variation (%)
V1–V148 h 16.2 15.6 33.9 2.4 22.9
V2–V1 17.7 18.3 26.3 1.4 15.5
V3–V1 25.0 24.9 31.2 0.9 23.4
Intraclass correlation coefficient
V1–V148 h 0.73 0.80 0.57 0.95 0.19
V2–V1 0.73 0.74 0.60 0.98 0.66
V3–V1 0.52 0.58 0.49 0.99 0.11
Values are expressed as mean (SD) unless otherwise stated.
FMD, flow-mediated dilatation; BLD, baseline diameter; VTI, velocity-time integral; TEM, technical error of measurement; React Hyper, reactive hyperaemia (%): (delta blood flow/
blood flow) × 100.
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clinical trials to test the safety and efficacy of pharmacological inter-
ventions.
Disturbance of endothelial function is an early event in the athero-
sclerotic process andclinical studies havedemonstrated its predictive
power for later CV events.14–16 Endothelial function assessment by
flow-mediated dilatation has been widely used in clinical practice
since the early 1990s.17 It has been shown to be accurate, to have
relevance to biology and to be associated with CV outcome.17–19
However, it has been criticized for being technically demanding
and operator dependent. Advances in the methodology (use of
stereotactic probeholder and analysis software for accurate edgede-
tection diameter) have greatly diminished the latter,20 however the
cost of ultrasound machine and inherent technical challenges affect-
ing the reproducibility of themethod in addition to the paucity of ex-
pertise has restricted its use to the clinical research setting.
The issue of FMD reproducibility has been a matter of intense
debate since CVs up to 51% have been reported among different
groups depending on the site of measurement and protocol
used.21 By standardizing the protocol and technical aspects of the
method, high reproducibility figures have been reported in specia-
lized laboratories in healthy populations and in those with disease
state under controlled conditions.8 However, limited information
exists for the reproducibility of the method in a multicentre setting
under less controlled conditions. Recently, Ghiadoni et al.22 docu-
mented the short-term reproducibility of FMD in a multicentre
setting among healthy volunteers. In the current study, we have
expanded these findings to provide information for the reproducibil-
ity of the method over a longer time interval but also for coronary
artery disease patients who are likely to be the target population
for many clinical trials.
Characterization of the flow-mediated dilatation signal has been a
matter of debate in different studies. Flow-mediated dilatation is typ-
ically expressed aspercentagechange in vessel diameter following re-
active hyperaemia. However, absolute change in diameter and FMD
normalized for shear rate have also been reported.12,23 In this repro-
ducibility study, wewere able to demonstrate comparable variability
between %FMDandFMDAbs at short-,medium-, and long-termeva-
luations. However, FMD/VTI was more variable over time. No asso-
ciationwas noted between reactive hyperaemia and %FMDandpoor
reproducibility was noted for reactive hyperaemia. Previous studies
have indicated that the measurement of the area under the flow
curve (AUC) rather than peak VTI might be more informative as a
stimulus for FMD response;24 however, other studies failed to
demonstrate the validity of AUC in FMD assessment.8
A number of physiological factors can impact on reactive hyper-
aemia including arterial stiffness, flow pattern, and blood viscosity,
Figure 1 (A) Bland–Altman plot showing no systematic bias and
good reproduciblity for short-term (within 48 h) assessment of
flow-mediated dilatation. Dotted lines represent 2 SD of the differ-
ences. (B) Bland–Altman plot showing no systematic bias and good
reproduciblity for medium-term (within 3 months) assessment of
flow-mediated dilatation. Dotted lines represent 2 SD of the differ-
ences. (C) Bland–Altman plot showing no systematic bias and
greater variability for long-term (within 9 months) assessment
of flow-mediated dilatation. Dotted lines represent 2 SD of the
differences.
Figure 2 Relationship between effect on maximum % change in
flow-mediated dilatation and number of subjects required in
various trial scenarios with different coefficient of variation (CV:
15% and CV: 25%) between centres assuming 80% power and 5%
significance for a parallel and crossover trial design.
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and these may affect its reproducibility.25 However, these para-
meters were not measured in this study and as such the explanation
for the variability of the reactive hyperaemia remains speculative.
Among the different measures, baseline diameter was the most re-
producible. Yeboah et al.16 have demonstrated that BLD may have
similar predictive value to FMD in older subjects. However, there is
no evidence to suggest that vessel size is nitric oxide dependent or
that itsmeasurements are responsive to interventions. Its clinical use-
fulness, thus, remains limited.
Dal-VESSEL is the first clinical trial to use FMD as a primary end-
point and was set out to establish the vascular impact of an HDL
raising drug, dalcetrapib in a population with coronary artery
disease.10 As expected lower absolute and percentage FMDs were
found in these patients with coronary artery disease and higher
range of CV risk factors compared with values reported for healthy
adults.11 We investigated all the participants who took part in the
substudy and were allocated to the placebo group to assess the vari-
ability of the method. The reproducibility figures for short- and
medium-term measurements were comparable with single-centre
values and suggest that FMD can be a valuable tool for clinical trials.
The long-term variability of the technique was higher. Although no
significant changes in the risk factor profile were noted in the partici-
pants with time, it is possible that physiological variability becomes
more significant over time. This can only partially be controlled for
factors known to affect endothelial function such as changes in tem-
perature, exercise, and infection.12 Some technical aspects for repeat
FMDmeasurements might also be difficult to control over long-time
intervals. For instance, identification of the same arterial segment
with comparable baseline diameters is necessary for serial FMDmea-
surements. In addition, declining in the scanning quality over time due
to detraining might also be considered. Sonographer variability was
performed only once for this study and although close monitoring
was performed for the quality of the data, deskilling with time for
the centres with low recruitment might be a possibility. The higher
rejection rate of the scans at 9 months and the reproducibility
results from this study suggest that over longer time interval, identi-
fication, and recognition of the same arterial segment might bemore
challenging even for experienced sonographers. As such this higher
variability should be carefully considered when sample size calcula-
tions are performed for clinical trials. In addition, previous studies
have demonstrated that FMD varies according to sex and to men-
strual cycle in females and that lower FMD values were reported in
African Americans compared with Caucasians.12 In this study,
however, we were unable to assess the reproducibility between dif-
ferent sexes and ethnic backgrounds as our population were mostly
males and of Caucasian origin.
A successful multicentre study using FMD requires adherence to a
single-scanning protocol and the use of standardized equipment.
Close monitoring of the involved centres and continuing training
for operators from centres with low recruitment rate is also neces-
sary. Centralized analysis by experienced readers is also important
to minimize the variability of the method. In this study, all the
images were analysed by three trained and certified readers who
hadhigh intra-rater and inter-rater reproducibility figures. Therefore,
the influence of the analysis process in the overall variability of the
method was minimized. The major component of FMD variability is
between subjects. Interestingly, the power curves which have been
constructed suggest that relatively small number of patients is ad-
equate to detect a difference in %FMD in both parallel and crossover
trials. Therefore, FMD can be an attractive endpoint in clinical trials
for the assessment of pharmacological interventions.
In conclusion, this study suggests that FMD is reproducible and
practical to use in a multicentre setting for short- and medium-term
pharmacological interventions providing that optimal training and
monitoring during the trial time period is performed.Our findings in-
dicate that longer-term assessment with FMD is more challenging as
physiological parameters are difficult to control over time. However,
the relatively small numbers required to detect an effect in %FMD
and its ability to detect early disturbances in endothelial physiology,
relevant to atherosclerotic disease progression, suggest that this
technique is an attractive option to assess safety and effectiveness
of a new pharmacological regime before embarking in large-scale ex-
pensive outcome trials.
Supplementary material
Supplementary material is available at European Heart Journal online.
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